PRIMARY CNS LYMPHOMA (PCNSL)
Clinical trials for PRIMARY CNS LYMPHOMA (PCNSL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CNS LYMPHOMA (PCNSL) trials appear
Sign up with your email to follow new studies for PRIMARY CNS LYMPHOMA (PCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat brain cancer: combo therapy enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or not responded to prior treatment. About 60 adults will take part to see if the combination can shrink tumors and how safe…
Matched conditions: PRIMARY CNS LYMPHOMA (PCNSL)
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated May 17, 2026 08:34 UTC
-
New cell therapy takes on hard-to-treat brain lymphoma
Disease control Recruiting nowThis study tests a new treatment called Anbal-cel for people with a type of lymphoma in the brain that has returned or not improved with standard therapy. The treatment uses a patient's own immune cells, which are collected, modified, and then given back to attack the cancer. The…
Matched conditions: PRIMARY CNS LYMPHOMA (PCNSL)
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated May 14, 2026 12:02 UTC